Stoke Therapeutics (STOK) Depreciation & Amortization (CF) (2018 - 2026)

Stoke Therapeutics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $439000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 7.97% year-over-year to $439000.0 in Q1 2026; TTM through Mar 2026 was $1.7 million, a 18.07% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, down 19.55% from the prior year.
• Depreciation & Amortization (CF) improved to $439000.0 in Q1 2026 per STOK's latest filing, from $405000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $637000.0 in Q3 2023 and bottomed at $247000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $540000.0 (2024), against an average of $495529.4.
• Across the five-year window, Depreciation & Amortization (CF) jumped 159.15% in 2022 and declined 26.23% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $609000.0 in 2022, then climbed by 2.46% to $624000.0 in 2023, then retreated by 12.02% to $549000.0 in 2024, then retreated by 26.23% to $405000.0 in 2025, then grew by 8.4% to $439000.0 in 2026.
• Per Business Quant, the three latest STOK Depreciation & Amortization (CF) figures stand at $439000.0 (Q1 2026), $405000.0 (Q4 2025), and $442000.0 (Q3 2025).